Apolipoprotein AI

Athens Research

Apolipoprotein AI

9

In Vitro Diagnostic, Cardiovascular Research, ALS, Diabetes

Research Use Only

≥95% by SDS-PAGE

Apolipoprotein A-I

Apolipoprotein AI (Apo AI), constituting 75% of HDL-associated apolipoproteins, is a critical for reverse cholesterol transport (RCT), mediating cholesterol efflux from peripheral tissues to the liver. As the primary structural component of HDL, Apo AI stabilizes discoidal HDL particles, activates lecithin-cholesterol acyltransferase (LCAT) to esterify cholesterol, and facilitates HDL maturatioN. Its anti-inflammatory properties include blocking T-cell–monocyte interactions, reducing TNF-alfa and IL-1bèta production, and neutralizing oxidized LDL. Normal plasma levels range from 90–130 mg/100 mL, with concentrations inversely correlating with coronary heart disease (CHD) risk. Deficiencies in Apo AI underlie Tangier disease, characterized by near-absent HDL, cholesterol-laden macrophages, and premature atherosclerosis. Mutations like APOA1 p.Leu202Arg cause systemic amyloidosis, leading to cardiac and renal dysfunction. Reduced Apo AI levels also associate with insulin resistance, impaired bèta-cell function, and diabetes progression. Conversely, Apo AI overexpression enhances macrophage-specific RCT, attenuating atherosclerosis.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

-80C

41116100